High-Throughput Cell Based Assay for the Identification of Drugs Targeting the NF-kB Signaling Pathway

Tech ID: 02-05

Summary

Researchers at National Jewish Health have developed a microscopy-based visual assay to measure the antigen-receptor activation of an intermediate molecule located upstream of NF-kB

Potential Applications

Identification of compounds as potential agents against inflammatory diseases, immune diseases and cancer

Advantages of Invention

The assay targets Bcl10, a specific intermediate protein of the NF- kB pathway, and it is compatible with epifluorescence/confocal microscopy

State of Development

Using cell lines developed in-house, National Jewish Health scientists have demonstrated that T cell receptor activation of NF-kB involves the dynamic relocalization of the signaling intermediate Bcl10. This protein movement can be visualized by confocal or epifluorescence microscopy using a fluorescent marker (such as GFP) or antibodies.


Publication

  • Schaefer BC, et. al. Proc Natl Acad Sci U S A. 2004 Jan 27; 101(4):1004-9. Epub 2004 Jan 14. PMID: 14724296


Patent Status
Issued U.S. Patent #7,169,570


Inventors
Brian Schaefer, PhD, Philippa Marrack, PhD and John Kappler, PhD


Licensing Status - This technology is available for licensing.

 

For Further Information, Contact:
Emmanuel Hilaire, PhD
Manager
Technology Transfer Office
National Jewish Health
1400 Jackson Street, Room M206b
Denver, CO 80206
Voice: 303.398.1262
Fax: 303.270.2352
HilaireE@njhealth.org

Featured Research 

Severe Allergic Reactions and the EpiPen
New research indicates that young children suffer allergic reactions to food more frequently than doctors realized, and that more caregivers need know how to use an EpiPen.

Faculty by Research

The discoveries made in the laboratories at National Jewish Health have a profound impact on the understanding and treatment of human disease.

Browse our Faculty by Area of Research.